Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy ...Middle East

PR Newswire - Economy

- Phase 1 clinical trial for smoking cessation expected to dose first patient in 4Q 2024 - - The study will evaluate the pharmacokinetics, safety and tolerability of the RespiRx™ Nicotine Inhaler compared to Nicotrol® Inhaler and combustible cigarettes - RICHMOND, Va., Oct. 1, 2024...

Read More Details
Finally We wish PressBee provided you with enough information of ( Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy )

Also on site :

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina
Zero Gravity Lifts off on Documentary Showcase
For sale (maybe): Trump’s red Tesla, low miles, almost new

Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy ...Middle East

Nigeria: Nigerian Grandmother Sacked From Cleaner Job At London University Over 'Misplaced Bracelet'

Zero Gravity Lifts off on Documentary Showcase

Uzbekistan Builds Where the West Withdrew

For sale (maybe): Trump’s red Tesla, low miles, almost new

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

ICE approves Georgia immigrant detention center following DOGE review

Trump Frustrated Over Lack of Progress in Ukraine-Russia Negotiations

Kennametal Announces Sale of Subsidiary in Goshen, IN

Ally Walker, Star of 'Sons of Anarchy,' Debuts Metaphysical Thriller 'The Light Runner'

Trump says the U.S. and China will resume trade talks Monday in London

Musk has a history of acrimonious breakups

U.S. and China to Hold Economic Talks in London

How Netflix’s ad business could become a $10 billion sleeper hit

AI Race Brings Energy Reliability Back into Spotlight

Elon Musk’s Fight With Trump Threatens $48 Billion in Government Contracts